TrialSignal
Clinical trial intelligence report
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06663787
Status
ACTIVE_NOT_RECRUITING
Phase
Observational
Sponsor
Nagoya City University
Executive brief
Investment-Ready Snapshot
This clinical trial aims to evaluate the status of circulating tumor DNA (ctDNA) in patients with HER2-positive metastatic breast cancer who have achieved a durable response to anti-HER2 treatment. The study utilizes the Signatera™ ctDNA assay to assess minimal residual disease (MRD) and explore potential new therapeutic strategies, including the possibility of de-escalating treatment in ctDNA-negative patients.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06663787
Indication
Breast Cancer, Metastatic
Modality
monoclonal antibody
Target
HER2-positive metastatic breast cancer
Intervention
Trastuzumab (Herceptin), SIgnatera
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.